Opthea Limited (OPT)

Market Cap	306.70M
Revenue (ttm)	385,275
Net Income (ttm)	-142.52M
Shares Out	82.85M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	6.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,396
Open	3.510
Previous Close	3.560
Day's Range	3.500 - 3.550
52-Week Range	1.600 - 4.420
Beta	0.73
Analysts	Strong Buy
Price Target	17.67 (+399.15%)
Earnings Date	Feb 28, 2024

About OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth fac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: OPT

Financial Performance

In 2023, Opthea's revenue was 385,275, an increase of 93.60% compared to the previous year's 199,005. Losses were -142.52 million, 53.6% more than in 2022.

Financial numbers in AUD

Analyst Forecast

According to 3 analysts, the average rating for OPT stock is "Strong Buy." The 12-month stock price forecast is $17.67, which is an increase of 399.15% from the latest price.

Price Target

$17.67

(399.15% upside)

Analyst Consensus: Strong Buy